Datapoint: FDA Approves Abecma for Multiple Myeloma

The FDA last week approved Bristol Myers Squibb’s and bluebird bio’s Abecma for the treatment of multiple myeloma in patients who have not responded to at least four previous rounds of treatment. Abecma is the first CAR-T cell therapy approved for multiple myeloma. This is the second CAR-T therapy for Bristol Myers, following Breyanzi’s lymphoma nod in February. Early data shows Breyanzi is currently covered for 9% of all insured lives, with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/29/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 1

Datapoint: FDA Approves Lexicon’s Heart Failure Drug

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 31

Datapoint: FDA Approves Celltrion’s Humira Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 30

Datapoint: Minnesota to Adopt Public Option Insurance

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today